Autoimmune Encephalitis is a disorder of the central nervous system caused by bodily substances, called antibodies. Antibodies normally help the body to prevent infections. However, in this disorder, the antibodies turn against the body itself and especially against cells in the brain and disturb the normal brain function. They are therefore called autoantibodies.
There is no specific therapy for patients with autoimmune encephalitis so far. At the moment, the symptoms are treated with approved medications such as cortisone and immunotherapies also used in oncology. These therapies are unspecified and aim to reduce the number of autoantibodies and to contain the autoimmune process. In this trial we aim to test a new therapy option: in this therapy the body cells producing autoantibodies will be specifically targeted by a substance called bortezomib.
The trial addresses patients with severe autoimmune encephalitis. The aim of the trial is to evaluate the efficacy and safety of bortezomib in patients with severe autoimmune encephalitis.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Autoimmune Encephalitis | Drug: Bortezomib Drug: Placebo | Phase 2 |
Autoimmune encephalitis is characterized by autoantibodies against neuronal surface antigens like the NMDA (N-methyl-D-aspartate) receptor or LGI1 (Leucin-rich glioma inactivated protein 1). So far, no specific therapy exists for this disease. Actual treatment includes combination therapies aiming for a reduction of pathogenic antibodies and containing the autoimmune process. In first line, patients are treated with plasmapheresis and cortisone. In second line, Rituximab and/or cyclophosphamide are administered. The response to these treatments are, however, often delayed and insufficient.
Therefore, we need a specific therapy aiming at the antibody-producing plasma cells.
Bortezomib is a proteasome inhibitor which interferes with NF-kB (nuclear factor kB) and the ubiquitin proteasome signaling pathway. Bortezomib acts preferably on cells with high protein synthesis - like plasma cells - and induces cell death in these cells. Bortezomib is used since more than a decade in chemotherapy of the multiple myeloma. Additionally, it is reported for systemic autoimmune diseases like lupus erythematodes that bortezomib leads to a depletion of plasma cells and therefore reduces the number of pathogenic antibodies and improves clinical outcome. The therapeutic potential of bortezomib for NMDAR encephalitis is described in a first case series with 5 patients.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | 1:1 randomization will be done centrally and stratified by site. Block randomization of variable block sizes will be used. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | The study drug will be provided blinded by the local pharmacy. |
Primary Purpose: | Treatment |
Official Title: | A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis |
Actual Study Start Date : | May 13, 2020 |
Estimated Primary Completion Date : | July 1, 2022 |
Estimated Study Completion Date : | December 31, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Interventional
1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
|
Drug: Bortezomib
1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
|
Placebo Comparator: Placebo
1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
|
Drug: Placebo
1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
Other Name: isotonic NaCl solution
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Christian Geis, Prof. | +49 (0) 3641 ext 9323413 | Christian.Geis@med.uni-jena.de | |
Contact: Jonathan Wickel, Dr. | +49 (0) 3641 ext 9323561 | Jonathan.Wickel@med.uni-jena.de |
Germany | |
Ludwig-Maximilians-Universität München, Klinikum Großhadern | Not yet recruiting |
München, Bayern, Germany, 81377 | |
Contact: Tania Kümpfel, Prof. +49894400 ext 74435 tania.kuempfel@med.uni-muenchen.de | |
Contact: Joachim Havla, Dr. +49894400 ext 74435 joachim.havla@med.uni-muenchen.de | |
Universitätsklinikum Würzburg | Not yet recruiting |
Würzburg, Bayern, Germany, 97080 | |
Contact: Claudia Sommer, Prof. +49931201 ext 23763 sommer_c@ukw.de | |
Contact: Kathrin Doppler, PD Dr. +49931201 ext 23787 doppler_K@ukw.de | |
Medizinische Hochschule Hannover | Recruiting |
Hannover, Niedersachen, Germany, 30625 | |
Contact: Kurt-Wolfram Suehs, PD Dr. +49511532 ext 2495 Suehs.Kurt-Wolfram@mh-hannover.de | |
Contact: Martin Stangel, Prof. +49511532 ext 6676 Stangel.Martin@mh-hannover.de | |
Charité - Universitätsmedizin Berlin, Klinik für Neurologie mit Experimenteller Neurologie | Recruiting |
Berlin, Germany, 10117 | |
Contact: Harald Pruess, PD Dr. +49 30 450560 ext 560 harald.pruess@charite.de | |
Contact: Peter Koertvelyessy, Dr. +49 30 450560 ext 164 p.koertvelyessy@dzne.de | |
Ruhr-Universität Bochum, St. Josef Hospital, Klinik für Neurologie | Recruiting |
Bochum, Germany, 44791 | |
Contact: Ilya Ayzenberg, PD Dr. +49 234 509 ext 6423 Ilya.Ayzenberg@ruhr-uni-bochum.de | |
Contact: Ruth Schneider, Dr. +49 234 509 ext 6433 ruth.schneider@rub.de | |
Universitätsmedizin Göttingen Georg-August-Universität, Klinik für Neurologie | Not yet recruiting |
Göttingen, Germany, 37075 | |
Contact: Dirk Fitzner, Dr. +49 551 39 ext 65593 d.fitzner@med.uni-goettingen.de | |
Universitätsklinikum Jena, Sektion Translationale Neuroimmunologie, Klinik für Neurologie | Recruiting |
Jena, Germany, 07747 | |
Contact: Christian Geis, Prof. +49-3641 ext -9323413 Christian.Geis@med.uni-jena.de | |
Contact: Jonathan Wickel, Dr. +49 3641 ext 9323561 Jonathan.Wickel@med.uni-jena.de | |
Klinik für Neurologie UKSH, Campus Kiel | Recruiting |
Kiel, Germany, 24105 | |
Contact: Frank Leypoldt, PD Dr. +49 431 500 ext 16209 frank.leypoldt@uksh.de | |
Contact: Klarissa Stuerner, Dr. +49 431 500 ext 23816 klarissa.stuerner@uksh.de | |
Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurologie | Not yet recruiting |
Leipzig, Germany, 04103 | |
Contact: Florian Then Berg, Prof. Dr. +49 341972 ext 4320 Florian.ThenBergh@medizin.uni-leipzig.de | |
Contact: Lars-Malte Teusser, Dr. +49 341972 ext 4320 lars-malte.teusser@medizin.uni-leipzig.de | |
Universitätsmedizin Mainz, Klinik und Poliklinik für Neurologie | Not yet recruiting |
Mainz, Germany, 55131 | |
Contact: Stefan Bittner, Prof. +49 6131 17 ext 2805 stefan.bittner@unimedizin-mainz.de | |
Contact: Felix Lüssi, PD Dr. +49 6131 17 ext 5278 felix.luessi@unimedizin-mainz.de | |
Universitätsklinikum Münster Klinik für Neurologie | Recruiting |
Münster, Germany, 48149 | |
Contact: Nico Melzer, PD Dr. +49 251 8348 ext 188 nico.melzer@ukm.de | |
Contact: Sven Meuth, Prof. +49 251 8346 ext 187 sven.meuth@ukm.de | |
Universitätsklinikum Ulm, Klinik für Neurologie Neurologische Ambulanz | Recruiting |
Ulm, Germany, 89081 | |
Contact: Jan Lewerenz, PD Dr. +49 731 500 ext 63146 jan.lewerenz@uni-ulm.de | |
Contact: Mabule Senel, Dr. +49 731 077 ext 5265 makbule.senel@uni-ulm.de |
Study Director: | Christian Geis, Prof. | University Hospital Jena |
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | June 12, 2019 | ||||||||
First Posted Date ICMJE | June 20, 2019 | ||||||||
Last Update Posted Date | February 10, 2021 | ||||||||
Actual Study Start Date ICMJE | May 13, 2020 | ||||||||
Estimated Primary Completion Date | July 1, 2022 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
modified Rankin-Score (mRS) [ Time Frame: 17 weeks after first administration of the study drug ] modified Rankin-Score from 0 = no symptoms to 6 = death
|
||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||
Change History | |||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||
Original Secondary Outcome Measures ICMJE |
|
||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis | ||||||||
Official Title ICMJE | A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis | ||||||||
Brief Summary |
Autoimmune Encephalitis is a disorder of the central nervous system caused by bodily substances, called antibodies. Antibodies normally help the body to prevent infections. However, in this disorder, the antibodies turn against the body itself and especially against cells in the brain and disturb the normal brain function. They are therefore called autoantibodies. There is no specific therapy for patients with autoimmune encephalitis so far. At the moment, the symptoms are treated with approved medications such as cortisone and immunotherapies also used in oncology. These therapies are unspecified and aim to reduce the number of autoantibodies and to contain the autoimmune process. In this trial we aim to test a new therapy option: in this therapy the body cells producing autoantibodies will be specifically targeted by a substance called bortezomib. The trial addresses patients with severe autoimmune encephalitis. The aim of the trial is to evaluate the efficacy and safety of bortezomib in patients with severe autoimmune encephalitis. |
||||||||
Detailed Description |
Autoimmune encephalitis is characterized by autoantibodies against neuronal surface antigens like the NMDA (N-methyl-D-aspartate) receptor or LGI1 (Leucin-rich glioma inactivated protein 1). So far, no specific therapy exists for this disease. Actual treatment includes combination therapies aiming for a reduction of pathogenic antibodies and containing the autoimmune process. In first line, patients are treated with plasmapheresis and cortisone. In second line, Rituximab and/or cyclophosphamide are administered. The response to these treatments are, however, often delayed and insufficient. Therefore, we need a specific therapy aiming at the antibody-producing plasma cells. Bortezomib is a proteasome inhibitor which interferes with NF-kB (nuclear factor kB) and the ubiquitin proteasome signaling pathway. Bortezomib acts preferably on cells with high protein synthesis - like plasma cells - and induces cell death in these cells. Bortezomib is used since more than a decade in chemotherapy of the multiple myeloma. Additionally, it is reported for systemic autoimmune diseases like lupus erythematodes that bortezomib leads to a depletion of plasma cells and therefore reduces the number of pathogenic antibodies and improves clinical outcome. The therapeutic potential of bortezomib for NMDAR encephalitis is described in a first case series with 5 patients. |
||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Phase 2 | ||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: 1:1 randomization will be done centrally and stratified by site. Block randomization of variable block sizes will be used. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: The study drug will be provided blinded by the local pharmacy. Primary Purpose: Treatment
|
||||||||
Condition ICMJE | Autoimmune Encephalitis | ||||||||
Intervention ICMJE |
|
||||||||
Study Arms ICMJE |
|
||||||||
Publications * | Wickel J, Chung HY, Platzer S, Lehmann T, Prüss H, Leypoldt F, Günther A, Scherag A, Geis C; GENERATE Study Group. Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis. Trials. 2020 Jul 8;21(1):625. doi: 10.1186/s13063-020-04516-7. | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
50 | ||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||
Estimated Study Completion Date ICMJE | December 31, 2022 | ||||||||
Estimated Primary Completion Date | July 1, 2022 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Sex/Gender ICMJE |
|
||||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | Germany | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT03993262 | ||||||||
Other Study ID Numbers ICMJE | ZKSJ0120 2019-001423-12 ( EudraCT Number ) DRKS00017497 ( Registry Identifier: DRKS ) |
||||||||
Has Data Monitoring Committee | Yes | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement ICMJE |
|
||||||||
Responsible Party | Christian Geis, Jena University Hospital | ||||||||
Study Sponsor ICMJE | Jena University Hospital | ||||||||
Collaborators ICMJE | Not Provided | ||||||||
Investigators ICMJE |
|
||||||||
PRS Account | Jena University Hospital | ||||||||
Verification Date | February 2021 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |